AI-generated from publicly available materials.Charles River Laboratories has partnered with Ipsen to leverage its virtual control group (VCG) database in toxicology studies, aiming to enhance the efficiency and ethical standards of safety assessments.
The collaboration focuses on integrating VCG data into Ipsen’s good laboratory practice-compliant toxicology study. This innovative approach seeks to reduce reliance on live animal subjects by using historical data to inform study outcomes, potentially streamlining timelines and improving data integrity. Charles River asserts that VCGs can significantly support the principles of the 3Rs—replacement, reduction, and refinement of animal use in research—while meeting regulatory demands.
Currently, Ipsen is dedicated to therapeutic areas including oncology, rare diseases, and neuroscience, with existing FDA-approved treatments such as Dysport and Iqirvo. The partnership underscores Charles River's commitment to modernizing safety studies through the application of advanced methodologies, as highlighted by Namandjé Bumpus, Ph.D., the company’s chief scientific and innovation officer.
Charles River's VCG platform is projected to decrease the necessity for animal testing in drug safety studies by up to 12%. This method not only enhances statistical power for identifying rare findings but also promotes a more uniform interpretation of results through extensive historical datasets. As regulatory bodies like the NIH and FDA advocate for new approach methodologies, this collaboration positions both companies at the forefront of ethical innovation in the life sciences sector.